Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hodgkin Lymphoma
100%
FDG PET-CT
100%
Brentuximab Vedotin
100%
Non-responders
85%
Overall Survival
57%
Complete Response
57%
4-cycle
42%
Positron Emission Tomography-computed Tomography (PET-CT)
42%
Lymphoma Patients
42%
Relapsed Lymphoma
42%
Progression-free Survival
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Treatment Line
28%
Monotherapy
14%
Treatment Outcome
14%
Median Overall Survival
14%
Predictive Ability
14%
Neutropenia
14%
High Efficacy
14%
Relapsed Patients
14%
Neuropathy
14%
Median Progression-free Survival
14%
Heavily Pretreated Patients
14%
High-dose Chemotherapy
14%
Refractory Hodgkin Lymphoma
14%
Relapsed or Refractory
14%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Positron Emission Tomography-Computed Tomography
100%
Brentuximab Vedotin
100%
Overall Survival
71%
Progression Free Survival
42%
Autologous Stem Cell Transplantation
28%
Neutropenia
14%
Monotherapy
14%
Neuropathy
14%
High Dose Chemotherapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hodgkin Disease
100%
Brentuximab Vedotin
100%
Overall Survival
71%
Progression Free Survival
42%
High Dose Chemotherapy
14%
Neuropathy
14%
Monotherapy
14%
Neutropenia
14%
Immunology and Microbiology
Brentuximab Vedotin
100%
Positron Emission Tomography-Computed Tomography
100%
Overall Survival
71%
Progression Free Survival
42%
Autologous Stem Cell Transplantation
28%
Drug Megadose
14%
Neuroscience
Positron Emission Tomography-Computed Tomography
100%
Brentuximab Vedotin
100%
Stem Cell
28%
Peripheral Neuropathy
14%